This Wiki is currently under construction
For the complete documentation index, see llms.txt. This page is also available as Markdown.

thiamine derivatives

Section: Complete Biochemistry → Thiamine Derivatives Reading level: Technical, with a plain-language summary Last reviewed: October 2026

Summary

Ordinary thiamine is a charged molecule that relies on saturable transporters to cross membranes. Beginning in the 1950s, mainly in Japan, chemists developed thiamine derivatives designed to be absorbed more efficiently. Almost all of them share one chemical trick: they are versions of thiamine in which the thiazolium ring has been opened and "locked" by attaching a group to the sulfur atom. This removes the permanent positive charge. Once inside the body, the lock is removed, the ring closes and ordinary thiamine is released.

Derivatives reliably produce higher blood thiamine levels than equivalent amounts of thiamine salts. They differ from each other in chemistry, in where they deliver thiamine (for example, whether they raise brain levels), and possibly in effects that are not explained by thiamine delivery alone. Clinical evidence varies from reasonable (some benfotiamine trials) to very limited or absent (several newer or less-studied compounds).

Naming: this wiki uses generic chemical names (and international non-proprietary names, where they exist) rather than brand names.

Why derivatives were developed

  • Saturable absorption: at dietary doses, thiamine uptake depends on the THTR-1 and THTR-2 transporters (see Thiamine Transporters).

  • Beriberi in Japan: a long history of thiamine deficiency drove Japanese research into better-absorbed forms.

  • A natural lead: in the early 1950s, Motonori Fujiwara and colleagues in Kyoto found that thiamine reacts with allicin from garlic to form allithiamine, a lipid-soluble disulfide that was better absorbed than thiamine. This discovery launched the development of synthetic analogues.

The key chemical idea

1

Open the thiazolium ring

At alkaline pH, the thiazolium ring of thiamine can open to an uncharged thiol form (see Thiamine Structure).

2

Trap the open form

Derivatives trap this open form by attaching a group to the sulfur:

  • through a disulfide bond (S–S) in the disulfide derivatives;

  • through a thioester bond (S–CO–R) in the S-acyl derivatives;

  • or as a cyclic thiocarbonate.

3

Cross membranes

Without the positive charge, many derivatives can cross membranes by passive diffusion, independently of thiamine transporters.

4

Release thiamine

Inside the body, disulfides are reduced (by glutathione and other thiol systems) and thioesters are hydrolysed (by thioesterases). This releases the thiol form, which closes spontaneously at physiological pH to give thiamine.

5

Form TPP

Thiamine is then phosphorylated by TPK1 to TPP as usual.

Classes and main compounds

Compound
Class
Description
Origin

Allithiamine

Disulfide

Thiamine allyl disulfide

Natural (garlic and Allium species); discovered early 1950s

Prosultiamine (thiamine propyl disulfide, TPD)

Disulfide

Propyl disulfide analogue

Synthetic, Japan

Fursultiamine (TTFD)

Disulfide

Thiamine tetrahydrofurfuryl disulfide

Synthetic, Japan, 1960s

Sulbutiamine

Disulfide (dimer)

Two O-isobutyryl thiamine units joined by a disulfide

Synthetic, Japan

Bisbentiamine

Disulfide (dimer)

O-benzoyl thiamine disulfide

Synthetic, Japan

Thiamine disulfide

Disulfide (dimer)

Two open-form thiamine molecules linked by S–S

Natural oxidation product; also used as a drug

Benfotiamine

S-acyl (thioester) with phosphate

S-benzoylthiamine O-monophosphate

Synthetic, Japan, late 1950s

Dibenzoylthiamine (DBT)

O,S-diacyl (thioester + ester)

O,S-dibenzoylthiamine

Synthetic, Japan; renewed research interest since ~2020

Cetotiamine

O,S-diacyl (carbonate)

O,S-diethoxycarbonylthiamine

Synthetic, Japan

Cycotiamine (cyclocarbothiamine)

Cyclic thiocarbonate

Open-form thiamine with sulfur and oxygen joined in a 1,3-oxathian-2-one ring

Synthetic, Japan, 1960s

Comparative pharmacology

Compound
Absorption
Blood thiamine
Brain thiamine (animal data)
Notes

Thiamine salts

Carrier-mediated at low doses; diffusion at high doses

Baseline comparator

Regulated by transporters

See Thiamine Salts & Forms

Benfotiamine

Dephosphorylated in the gut to lipophilic S-benzoylthiamine, then absorbed

Highest of the compounds compared in human studies

Little or no increase in mice

Not lipid-soluble itself; poorly soluble in water and organic solvents

Fursultiamine (TTFD)

Lipophilic; passive diffusion

Higher than thiamine salts

Increases reported

Garlic-like odour

Sulbutiamine

Highly lipophilic

Higher than thiamine salts

Increases thiamine and phosphate esters in rat brain

Developed for central effects

Dibenzoylthiamine

Lipophilic

Higher than thiamine in mice

Data limited

Mainly preclinical

In a human crossover study comparing oral derivatives, benfotiamine produced the highest plasma and erythrocyte thiamine levels, followed by fursultiamine, and then thiamine disulfide.

Beyond thiamine delivery

Several studies, mainly in cells and rodents, report that thioester derivatives (benfotiamine and dibenzoylthiamine) have antioxidant and anti-inflammatory effects that do not appear to be explained by increases in TPP or TPP-dependent enzyme activity. Proposed explanations include:

  • activation of the Nrf2 antioxidant pathway;

  • effects of as-yet-unidentified open-thiazole-ring metabolites;

  • modulation of signalling enzymes such as GSK-3β.

These mechanisms are preclinical hypotheses. The active metabolites have not been identified.

Clinical evidence at a glance

Compound
Best clinical evidence

Benfotiamine

Several randomized controlled trials (diabetic neuropathy, nephropathy, Alzheimer's disease); a larger Alzheimer's trial is under way

Fursultiamine (TTFD)

Small open-label studies; long clinical use in Japan

Sulbutiamine

Older trials in fatigue (asthenia); small open-label studies

Prosultiamine

Small open-label trial in HTLV-1-associated myelopathy

Dibenzoylthiamine

No published controlled human trials found as of October 2026

Others

Little modern published research

Safety overview

  • Thiamine derivatives have generally been well tolerated in published studies, including benfotiamine for up to 12–24 months.

  • Long-term safety data are much more limited than for thiamine itself, especially for sulbutiamine and dibenzoylthiamine.

  • Disulfides release thiol by-products (for example, tetrahydrofurfuryl mercaptan from TTFD), which can cause a garlic-like odour.

  • Regulatory status varies: some derivatives are licensed medicines in some countries and sold as supplements in others.

Pages in this section

  • Benfotiamine

  • Thiamine Tetrahydrofurfuryl Disulfide (TTFD)

  • Dibenzoylthiamine (DBT)

  • Sulbutiamine

  • Novel Derivatives & Future Research

Open questions

  • Which derivative, if any, best delivers thiamine to the human brain?

  • Which effects are due to thiamine delivery, and which to other metabolites?

  • How do derivatives compare head-to-head on clinical outcomes? Such trials are almost entirely lacking.

  • What are the long-term safety profiles of the less-studied compounds?

  • Thiamine Structure

  • Thiamine Transporters

  • Mechanisms of Malabsorption

  • Common Misconceptions

References

  1. Fujiwara M. Allithiamine and its properties. Journal of Nutritional Science and Vitaminology. 1976;22(Suppl):57–62.

  2. Lonsdale D. Thiamine tetrahydrofurfuryl disulfide: a little known therapeutic agent. Medical Science Monitor. 2004;10(9):RA199–RA203.

  3. Bitsch R, et al. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. Annals of Nutrition and Metabolism. 1991;35(5):292–296.

  4. Greb A, Bitsch R. Comparative bioavailability of various thiamine derivatives after oral administration. International Journal of Clinical Pharmacology and Therapeutics. 1998;36(4):216–221.

  5. Volvert ML, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacology. 2008;8:10.

  6. Bettendorff L, et al. Injectable sulbutiamine induces an increase in thiamine concentrations and thiamine phosphate esters in rat brain. Biochemical Pharmacology. 1990;40(11):2557–2560.

  7. Sambon M, Wins P, Bettendorff L. Neuroprotective effects of thiamine and precursors with higher bioavailability: focus on benfotiamine and dibenzoylthiamine. International Journal of Molecular Sciences. 2021;22(11):5418.

  8. [Authors to be confirmed]. Synthetic thioesters of thiamine: promising tools for slowing progression of neurodegenerative diseases. International Journal of Molecular Sciences. 2023;24(14):11296.

  9. Nakamura T, et al. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial. BMC Medicine. 2013;11:182.

Editorial note: This page describes mechanisms and published evidence. It is not medical advice and does not recommend doses. Suggest corrections or new sources via the feedback link.

Was this helpful?